depei wu
The First Affiliated Hospital of Soochow University
8
4
1
N/A
0
7
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+7 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Xiaojin Wu
The First Affiliated Hospital of Soochow University
Shared therapeutic areas:
Worked with same sponsors:
heng Mei
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shared therapeutic areas:
Worked with same sponsors:
Weili Zhao, PhD
Ruijin Hospital
Shared therapeutic areas:
Worked with same sponsors:
Huiqiang Huang, PhD
Sun Yat-sen University
Shared therapeutic areas:
Worked with same sponsors:
Dehui Zou
Hematology Hospital, Chinese Academy of Medical Sciences
Shared therapeutic areas:
Worked with same sponsors:
Zhifeng Li
The First Hospital of Xiamen University
Shared therapeutic areas:
Worked with same sponsors:
Qingyuan Zhang
Harbin Medical University Tumor Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jianqiu Wu
Jiangsu Provincial Tumor Hospital
Shared therapeutic areas:
Worked with same sponsors:
Liang Huang, PhD
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Shared therapeutic areas:
Worked with same sponsors:
Hongmei Jing
Peking University Third Hospital
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
Relmacabtagene Autoleucel in Patients With LBCL
GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT
Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
All 8 trials loaded